News for CNTG Stock

CENTOGENE Closes Strategic Transaction with Private Equity Group Charme Capital Partners CENTOGENE Announces Voting Results of Extraordinary General Meeting CENTOGENE Signs Strategic Transaction With Private Equity Group Charme Capital Partners CENTOGENE Data on Novel Genetic Risk Factor for Parkinson’s Disease in The Lancet Neurology CENTOGENE Receives Delisting Notice From Nasdaq CENTOGENE Publication in Brain Journal Reveals 15% of Parkinson’s Disease Cases Are Linked to Genetic Factors C-Path and CENTOGENE MOU to Enhance Collaboration in Lysosomal Disease Research and Drug Development CENTOGENE Announces Adoption of All Resolutions Tabled at 2024 Annual General Meeting CENTOGENE Reports Full Year 2023 Financial Results and Recent Business Highlights CENTOGENE Secures Approx. $20 Million to Strengthen Cash Position CENTOGENE and Evotec Discover Promising New Molecule to Treat Gaucher Disease CENTOGENE Biodatabank Grows to Incorporate Disease Insights From Over 850,000 Diverse Patients CENTOGENE Receives Nasdaq Non-Compliance Notice CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders CENTOGENE Collaborates on Research Published in Science Showing Immunopathological Landscape of Human Pre-TCRα Deficiency CENTOGENE Announces Receipt of Nasdaq Notice of Delisting and Intention to Request a Hearing CENTOGENE Explores Strategic Alternatives CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration CENTOGENE Receives French Research Tax Credit Accreditation CENTOGENE and The Michael J. Fox Foundation Announce Research Project to Validate Genetic Risk Factors of Parkinson’s Disease Using Multiomics CENTOGENE Announces Preliminary Full Year 2023 Revenue CENTOGENE Announces Voting Results of Extraordinary General Meeting CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment Milestone CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture Transaction CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and Parkinsonism CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic Offering CENTOGENE to Present at H.C. Wainwright 25th Annual Global Investment Conference CENTOGENE Reports First Half 2023 Financial Results CENTOGENE Announces Publication Establishing Lyso-Gb1 as a Predictive Biomarker for Gaucher Disease Patients CENTOGENE Receives Nasdaq Non-Compliance Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency CENTOGENE to Participate in Upcoming Conferences in August CENTOGENE Regains Compliance With Nasdaq Listing Requirements CENTOGENE Biodatabank Reveals Unique Genetic Variants in World's Largest Niemann-Pick Type C1 Disease Cohort Lifera and CENTOGENE, Enter Strategic Collaboration - Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing CENTOGENE Announces Approval of All Resolutions Tabled at 2023 Annual General Meeting CENTOGENE and Lifera, a Biopharma Company Owned by the PIF, Enter Strategic Collaboration – Forming Saudi Arabian Joint Venture to Increase Access to Leading Data-Driven Multiomic Testing and Securing CENTOGENE $30 Million Investment CENTOGENE Receives Nasdaq Notification Regarding Minimum Market Value of Publicly Held Shares Deficiency CENTOGENE Reports Full Year 2022 Financial Results CENTOGENE to Participate in Upcoming Conferences in May CENTOGENE Receives Nasdaq Non-Compliance Notice CENTOGENE Accelerates Global Genetic Data Interpretation, Launching FilterTool Application as Accessory to CentoCloud® Bioinformatics Pipeline CENTOGENE to Participate in Upcoming Conferences in April CENTOGENE Launches NEW CentoGenome®, World’s Most Comprehensive Whole Genome Sequencing Solution for Diagnosis of Rare and Neurodegenerative Diseases CENTOGENE Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders CENTOGENE Appoints Ian Rentsch as Chief Commercial Officer and General Manager - Pharma CENTOGENE to Participate in Upcoming Conferences in March In the Lead-Up to Rare Disease Day, CENTOGENE Expands Observational Study to Advance the Genetic Understanding of Frontotemporal Dementia (FTD) CENTOGENE Regains Compliance With Nasdaq Listing Requirements CENTOGENE to Participate in Upcoming Conferences in February in the Lead Up to Rare Disease Day Twist Bioscience and CENTOGENE Launch Three Panels to Advance Rare Disease and Hereditary Cancer Research and Support Diagnostics CENTOGENE and Denali Therapeutics Extend World’s Largest Observational Study on Parkinson’s Disease Genetics Premier Research and CENTOGENE Launch Strategic Partnership to Accelerate and De-Risk Rare Disease Clinical Development CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco CENTOGENE Reports Second Quarter and First Half 2022 Financial Results CENTOGENE Receives Nasdaq Non-Compliance Notice CENTOGENE to Participate in Upcoming Conferences in December CENTOGENE to Participate in Upcoming Conferences in November CENTOGENE Launches Rare and Neurodegenerative Disease Biodata Network CENTOGENE to Participate in Upcoming Partnering Conferences in October CENTOGENE Reaches 12,500 Patient Milestone in World’s Largest Observational Study on Parkinson’s Disease Genetics CENTOGENE to Present at Upcoming Investor & Partnering Conferences in September CENTOGENE Reports First Quarter 2022 Financial Results CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meeting CENTOGENE and Agios Expand Partnership for Clinical Development of PYRUKYND® (mitapivat) to Treat Children With Rare Blood Disease CENTOGENE’s CentoCloud® Is Now CE-Marked as One of the Only Decentralized SaaS Platforms Compliant With European IVD Regulatory Framework CENTOGENE Contributes to Europe-Wide Efforts to Update Guidelines for Whole Genome Sequencing (WGS) in Rare Disease Diagnostics CENTOGENE to Present at the H.C. Wainwright Global Investment Conference CENTOGENE and Takeda Extend Market Access and Expansion Partnership to Advance Patient Care Globally CENTOGENE Reports Fourth Quarter and Full Year 2021 Financial Results CENTOGENE CEO Kim Stratton to Speak at BIO-Europe Spring® 2022 Conference CENTOGENE to Announce Fourth Quarter and Fiscal Year 2021 Financial Results on March 30, 2022 CENTOGENE Announces Expansion of Data Access and Collaboration Agreement With Pfizer CENTOGENE Announces Voting Results of Extraordinary General Meeting CENTOGENE Announces CFO Transition and Appointment of Miguel Coego Rios as EVP Finance & Legal and Interim CFO CENTOGENE Announces Nomination of Andreas Busch to Supervisory Board CENTOGENE Announces Nomination of Kim Stratton as Chief Executive Officer CENTOGENE Announces USD 62 Million Aggregate Equity and Debt Financings to Support Growth Plan CENTOGENE Joins Forces With Insilico Medicine for Niemann-Pick Disease Type C (NPC) Target Discovery, Applying Artificial Intelligence (AI) to Accelerate Orphan Drug Development CENTOGENE’s CentoCloud® Set to Revolutionize Rare Disease Diagnostics With Decentralized SaaS Platform for Laboratories Around the World CENTOGENE Wins Award in Digital Healthcare Innovation for Artificial Intelligence (AI) Platform Leading Biomarker Discovery CENTOGENE Announces CEO to Take Temporary Medical Leave of Absence – Biopharmaceutical Industry Veteran Kim Stratton Appointed as Interim CEO CENTOGENE Reports Third Quarter 2021 Financial Results CENTOGENE to Announce Third Quarter 2021 Financial Results on November 24, 2021 CENTOGENE Expands Partnership With Agios to Generate Novel Insights Into Rare Blood Diseases CENTOGENE Enrolls First Patient in Frontotemporal Dementia (FTD) Clinical Study Twist Bioscience and CENTOGENE to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases CENTOGENE and Twist Bioscience to Develop Advanced Sequencing Tools to Make Genetic Testing Rapidly Accessible for More Patients With Rare Diseases CENTOGENE’s Ground-Breaking Family Genetic Research Published in the New England Journal of Medicine Reveals Path to Potential Cure for Structural Birth Defects CENTOGENE Reports Second Quarter 2021 Financial Results CENTOGENE to Announce Second Quarter 2021 Financial Results on September 7, 2021 CENTOGENE Appoints Patrice P. Denèfle as Chief Scientific Officer to Lead Its Data-Driven Approach to Reinvent Rare Disease Drug Discovery and Development CENTOGENE Announces Shareholders Approve All Resolutions at Annual General Meeting CENTOGENE Sets Mission to Enable the Cure of 100 Rare Diseases Within the Next 10 Years CENTOGENE Reports First Quarter 2021 Financial Results in the Lead Up to Virtual Investor Event CENTOGENE to Announce Q1 2021 Financial Results on June 16, 2021 CENTOGENE Announces Virtual Investor Event CENTOGENE Initiates EFRONT Study to Identify Patients With Genetic Forms of Frontotemporal Dementia CENTOGENE Launches NEW CentoXome® - An Enhanced Whole Exome Sequencing Solution CENTOGENE Announces the Nomination of Rene Just as Chief Financial Officer CENTOGENE Appoints Michael Motz as Chief Commercial Officer, Pharmaceuticals CENTOGENE Extends Global Parkinson’s Disease Study New CentoMD® 6.0 Update Brings Deeper Insights Into Rare Diseases CENTOGENE Discovers Six New Rare Diseases by Leveraging the Strength of Its Bio/Databank CENTOGENE Reports Record Fourth Quarter and Full Year 2020 Financial Results CENTOGENE Extends Partnership With Takeda CENTOGENE to Announce Full Year 2020 Financial Results on April 15, 2021 CENTOGENE’s Information Security Management System Awarded ISO/IEC 27001:2017 Accreditation CENTOGENE Reaches 10,000 Participant Milestone in Global Parkinson’s Disease Study CENTOGENE Announces Voting Results of Extraordinary General Meeting CENTOGENE Reports Third-Quarter 2020 Financial Results and Increases Full Year Guidance CENTOGENE to Report Third-Quarter 2020 Financial Results on December 16, 2020 CENTOGENE and Alnylam Pharmaceuticals Launch a New Clinical Program Aimed at Revolutionizing the Diagnosis of Hereditary Transthyretin-Related Amyloidosis (“ATTRv”) CENTOGENE Expands Partnership with PTC Therapeutics to Generate New Insights for Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency CENTOGENE Announces Nomination of Jonathan Sheldon to Supervisory Board Fujirebio Europe and CENTOGENE Enter Partnership to Provide Rapid and High-Quality Preventive SARS-CoV-2 Antigen Testing CENTOGENE Opens Walk-In COVID-19 Testing Facility at Berlin Brandenburg Airport CENTOGENE Increases Full-Year 2020 Guidance CENTOGENE Announces Leadership Transition CENTOGENE Receives FDA Emergency Use Authorization for SARS-CoV-2 RT-PCR Assay for Individuals Without Symptoms or Other Reasons to Suspect COVID-19 Collaboration Between CENTOGENE and U-Diagnostics Increases COVID-19 Testing Capacities in the Netherlands CENTOGENE’s Information Security Management System Awarded ISO/IEC 27001:2017 Accreditation CENTOGENE Reports First Half 2020 Financial Results CENTOGENE Opens Walk-In COVID-19 Testing Facility at Düsseldorf Airport CENTOGENE to Report First Half 2020 Financial Results on September 23, 2020 CENTOGENE Expands COVID-19 Testing Capacity at Frankfurt Airport CENTOGENE Publishes Huge Dataset That Supports Genome Sequencing as a First-Line Diagnostic Test CENTOGENE and Evotec Expand Collaboration Into Gaucher Disease CENTOGENE Opens Walk-In COVID-19 Testing Facility at Hamburg Airport CentoMD® Update Reveals Further Insights Into Rare Diseases CENTOGENE Receives FDA Emergency Use Authorization for COVID-19 Molecular Diagnostic Test CENTOGENE Announces Change in Supervisory Board CENTOGENE to Report First-Quarter 2020 Financial Results on June 15, 2020 CENTOGENE Announces Statewide COVID-19 Testing for Nursing Homes in Mecklenburg-Western Pomerania, Germany CENTOGENE Expands Senior Leadership Team with Newly Appointed Senior Vice President Communication and Marketing CENTOGENE Announces Convenient At-Home Coronavirus Test Solution Now Available in Germany on Online Marketplace CENTOGENE Announces the Scientific Publication of a holistic solution in the preventive testing of COVID-19 CENTOGENE Announces Partnership with OESIS Network for COVID-19 PCR Testing for US School Populations CENTOGENE, Lufthansa, and Fraport Launch the First Walk-In COVID-19 Testing Facility in Germany at Frankfurt Airport CENTOGENE Reports First-Quarter 2020 Financial Results and Corporate Progress CENTOGENE Announces Changes in Senior Management Team Blueprint for Germany: CENTOGENE Provides Coronavirus Testing for German High School CENTOGENE Announces Pricing of Primary and Secondary Public Offering of Common Shares CENTOGENE Announces Proposed Primary and Secondary Public Offering of Common Shares